The purpose of the study is to assess the effect of dalpiciclib plus letrozole and capecitabine of first-line treatment with high-risk for HR- positive /HER-2 negative advanced breast cancer
to assess the effect of dalpiciclib plus letrozole and capecitabine of first-line treatment with breast cancer